# Zilebesiran PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zilebesiran

> The next catalyst for zilebesiran, sponsored by ALNYLAM PHARMACEUTICALS, INC. (ALNY), is its topline data readout, Sep to Dec 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | zilebesiran |
| Codes |  |
| Sponsor | ALNYLAM PHARMACEUTICALS, INC. (ALNY) https://sec-api.dev/companies/alny/catalysts |
| Indications | [uncontrolled hypertension](https://sec-api.dev/indications/uncontrolled-hypertension), High Cardiovascular Risk, High Risk Cardiovascular Disease |
| Modality | sirna |
| FDA designations | none disclosed |

## Timeline

### Sep 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-02-13, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001178670-26-000076): "In September 2023, we announced positive topline results from the KARDIA-1 Phase 2 clinical trial of zilebesiran, triggering the achievement of the development milestone of $84.5 million payable to Blackstone Life Sciences in 16 equal quarterly payments over four years, as consideration for Blackstone Life Sciences' funding for Phase 2 clinical development costs of zilebesiran." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm
- SEC Form 10-Q (accession 0001178670-26-000062): "In September 2023, we announced positive topline results from the KARDIA-1 Phase 2 clinical trial of zilebesiran, triggering the achievement of the development milestone of $84.5 million payable to Blackstone Life Sciences in 16 equal quarterly payments over four years, as consideration for Blackstone Life Sciences' funding for Phase 2 clinical development costs of zilebesiran." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-028605): "In September 2023, we announced positive topline results from the KARDIA-1 Phase 2 clinical trial of zilebesiran, triggering the achievement of the development milestone of $84.5 million payable to Blackstone Life Sciences in 16 equal quarterly payments over four years, as consideration for Blackstone Life Sciences' funding for Phase 2 clinical development costs of zilebesiran." https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm
- SEC Form 10-K (accession 0001628280-26-007497): "In September 2023, we announced positive topline results from the KARDIA-1 Phase 2 clinical trial of zilebesiran, triggering the achievement of the development milestone of $84.5 million payable to Blackstone Life Sciences in 16 equal quarterly payments over four years, as consideration for Blackstone Life Sciences' funding for Phase 2 clinical development costs of zilebesiran." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In September 2023, we announced positive topline results from the KARDIA-1 Phase 2 clinical trial of zilebesiran, triggering the achievement of a development milestone of $84.5 million payable to Blackstone Life Sciences in 16 equal quarterly payments over four years." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In September 2023, we reported positive topline results from the KARDIA-1 clinical trial, with zilebesiran meeting the primary endpoint and demonstrating greater than 15mmHg reduction of systolic blood pressure at three months of treatment compared to placebo at the two highest single doses evaluated." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### Mar 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-02-13, last confirmed 2025-10-30.
- SEC Form 10-Q (accession 0001628280-25-047345): "In March 2024, we reported positive topline results from our KARDIA-2 clinical trial, which is designed to evaluate the safety and efficacy of zilebesiran administered biannually as a concomitant therapy in patients whose blood pressure is not adequately controlled by a standard of care antihypertensive medication." https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm
- SEC Form 10-Q (accession 0001178670-25-000090): "In March 2024, we reported positive topline results from our KARDIA-2 clinical trial, which is designed to evaluate the safety and efficacy of zilebesiran administered biannually as a concomitant therapy in patients whose blood pressure is not adequately controlled by a standard of care antihypertensive medication." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000090/alny-20250630.htm
- SEC Form 10-Q (accession 0001178670-25-000052): "In March 2024, we reported positive topline results from our KARDIA-2 clinical trial, which is designed to evaluate the safety and efficacy of zilebesiran administered biannually as a concomitant therapy in patients whose blood pressure is not adequately controlled by a standard of care antihypertensive medication." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In March 2024, we reported positive topline results from our KARDIA-2 clinical trial, which is designed to evaluate the safety and efficacy of zilebesiran administered biannually as a concomitant therapy in patients whose blood pressure is not adequately controlled by a standard of care antihypertensive medication." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In April 2024, we reported positive topline results from the KARDIA-2 clinical trial, with zilebesiran meeting the primary endpoint and demonstrating additive, placebo-adjusted reductions of up to 12.1 mmHg in 24-hour mean systolic blood pressure at Month 3 when zilebesiran was added to a thiazide-like diuretic, calcium channel blocker or angiotensin receptor blocker." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### Apr 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-02-13, last confirmed 2025-05-01.
- SEC Form 10-Q (accession 0001178670-25-000052): "In April 2024, we dosed the first patient in our KARDIA-3 Phase 2 clinical trial, which is designed to evaluate the efficacy and safety of zilebesiran as an add-on therapy in adult patients with high cardiovascular risk and uncontrolled hypertension despite treatment with two to four standard of care antihypertensive medications, and we expect to report results from the KARDIA-3 Phase 2 clinical trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In April 2024, we dosed the first patient in our KARDIA-3 Phase 2 clinical trial, which is designed to evaluate the efficacy and safety of zilebesiran as an add-on therapy in adult patients with high cardiovascular risk and uncontrolled hypertension despite treatment with two to four standard of care antihypertensive medications, and we expect to report results from the KARDIA-3 Phase 2 clinical trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "In April 2024, we initiated the KARDIA-3 Phase 2 clinical trial, which is evaluating zilebesiran as an add-on therapy in high cardiovascular risk patients with uncontrolled hypertension despite receiving two or more antihypertensives." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

### June 19, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: High Cardiovascular Risk; Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Alnylam Pharmaceuticals." https://clinicaltrials.gov/study/NCT06272487

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-02-13, last confirmed 2026-10-29.
- SEC Form 10-K (accession 0001178670-25-000026): "We plan to announce topline results from KARDIA-3, and to initiate a Phase 3 cardiovascular outcomes trial of zilebesiran, in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-Q (accession 0001178670-26-000076): "Net revenues from collaborations decreased during the three and nine months ended September 30, 2026, as compared to the same periods in 2025, primarily due to the recognition of $300.0 million of milestone revenue under our collaboration with Roche in September 2025 associated with the dosing of the first patient in the ZENITH Phase 3 clinical trial of zilebesiran, partially offset by increased revenue under the Roche collaboration during 2026, due to higher reimbursable development activities related to the same clinical trial." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm

### Sep 2025: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: uncontrolled hypertension.
- First seen 2025-10-30, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001178670-26-000076): "In September 2025, we initiated a Phase 3 cardiovascular outcomes clinical trial, ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), which is designed to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension on two or more antihypertensives, one being a diuretic." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm
- SEC Form 10-Q (accession 0001178670-26-000062): "In September 2025, we initiated a Phase 3 cardiovascular outcomes clinical trial, ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), which is designed to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension on two or more antihypertensives, one being a diuretic." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-028605): "In September 2025, we initiated a Phase 3 cardiovascular outcomes clinical trial, ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), which is designed to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension on two or more antihypertensives, one being a diuretic." https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm
- SEC Form 10-K (accession 0001628280-26-007497): "In September 2025, we initiated a Phase 3 cardiovascular outcomes clinical trial, ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), which is designed to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension on two or more antihypertensives, one being a diuretic." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-047345): "In September 2025, we initiated a Phase 3 cardiovascular outcomes clinical trial, ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), which is designed to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension on two or more antihypertensives, one being a diuretic." https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm

### Sep to Dec 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07181109 (Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." https://clinicaltrials.gov/study/NCT07181109

### September 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07181109 (Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." https://clinicaltrials.gov/study/NCT07181109

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zilebesiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zilebesiran PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zilebesiran

```bibtex
@misc{secapidev_pdufa_zilebesiran_20261116,
  title        = {Zilebesiran PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zilebesiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zilebesiran_20261116","title":"Zilebesiran PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zilebesiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
